Tralokinumab for Chronic Hand Eczema: A 52 Week Observational Case Series

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Chronic hand eczema (CHE) significantly impacts quality of life and work productivity.
• Limited systemic treatment options exist for CHE.
• Evidence for tralokinumab, an IL-13 inhibitor, in CHE is scarce.

Purpose of the Study:

• To assess the effectiveness and safety of tralokinumab in adults with moderate-to-severe CHE.
• To evaluate tralokinumab in patients refractory to topical treatments.

Main Methods:

• Retrospective observational study at a tertiary dermatology center.
• Included adults with moderate-to-severe CHE unresponsive to topical corticosteroids or calcineurin inhibitors.
• Patients received subcutaneous tralokinumab; Hand Eczema Severity Index (HECSI) assessed at multiple time points.

Main Results:

• 100% of patients achieved HECSI-75, 92.3% HECSI-90, and 53.8% HECSI-100 by week 52.
• Dose adjustment to 300 mg every 4 weeks was feasible in 62.5% while maintaining response.
• No serious adverse events were reported.

Conclusions:

• Tralokinumab demonstrates clinically meaningful improvement in severe CHE.
• The drug is well-tolerated, including in hyperkeratotic and non-atopic forms.
• Response rates and maintenance suggest tralokinumab's potential role in CHE management.